Letters sent to healthcare professionals in October 2016

A summary of recent safety letters sent to relevant healthcare professionals

• From: Medicines and Healthcare products Regulatory Agency
• Published: 8 November 2016

• Therapeutic area: Cancer, Endocrinology, diabetology and metabolism, Haematology, Respiratory disease and allergy, Urology and nephrology

In October 2016, the following letters were sent to relevant healthcare professionals:

• Flolan (epoprostenol): new thermostable formulation (solvent pH 12) available from October 2016, with differences in storage and administration from previous formulation (pH 10.5)
• Teva levothyroxine: reintroduction to market and introduction of new tablet strengths (letter for Clinical Commissioning Groups, and for pharmacists and dispensers); see also further information here
• Blincyto▼ (blinatumomab): cases of pancreatitis

Article citation: Drug Safety Update volume 10 issue 4, November 2016: 3.

Published 8 November 2016